ICOSLG and systemic lupus erythematosus: Rozibafusp alfa (AMG 570), a bispecific inhibitory molecule targeting both ICOSL and B-cell activating factor BAFF, is currently undergoing phase I clinical trials and is expected to be more efficient in the treatment of autoimmune diseases such as SLE and RA (124, 125).